BioNotebook: Three licenses and a royalty deal; Ligand/Avion, RedHill/RESprotect and more
This article was originally published in Scrip
Summer is for relaxing, but biotechnology companies like Avion Pharmaceuticals and investors like DRI Capital remain focused on licensing key programs or buying new revenue streams.
You may also be interested in...
CEO John Glasspool spoke with Scrip about why Anthos believes it has a good shot against big competitors in a market that is expected to generate blockbuster sales across multiple products.
Private Company Edition: Sironax completed a $200m series B round while IDRx launched with $122m and OriCell raised $120m in series C funds, joining end-of-July $100m-plus fundraiser Carmot Therapeutics, which closed a $160m series D financing.
Amgen is acquiring a pipeline-in-a-pill with ChemoCentryx’s Tavneos, currently approved for ANCA-associated vasculitis, at a time when the company’s existing portfolio is struggling to maintain sales growth.